These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32336655)

  • 21. Does HIV Pre-Exposure Prophylaxis Modify the Effect of Partnership Characteristics on Condom Use? A Cross-Sectional Study of Sexual Partnerships Among Men Who Have Sex with Men in San Francisco, California.
    Prescott MR; Hern J; Petersen M; Santos GM
    AIDS Patient Care STDS; 2019 Apr; 33(4):167-174. PubMed ID: 30932698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Race and Other Social Determinants of Health With HIV Pre-Exposure Prophylaxis Use: A County-Level Analysis Using the PrEP-to-Need Ratio.
    Doherty R; Walsh JL; Quinn KG; John SA
    AIDS Educ Prev; 2022 Jun; 34(3):183-194. PubMed ID: 35647866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015-2018).
    Tan DHS; Dashwood TM; Wilton J; Kroch A; Gomes T; Martins D
    Can J Public Health; 2021 Feb; 112(1):89-96. PubMed ID: 32529552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in HIV Pre-exposure Prophylaxis (PrEP) Coverage at State and County Level During the COVID-19 Pandemic in the United States.
    Fallahi M; Guadamuz JS; Shooshtari A; Qato DM
    AIDS Behav; 2024 Mar; 28(3):799-804. PubMed ID: 37751110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Demographic, clinical guideline criteria, Medicaid expansion and state of residency: a multilevel analysis of PrEP use on a large US sample.
    Carneiro PB; Mirzayi C; Jones S; Rendina J; Grov C
    BMJ Open; 2022 Feb; 12(2):e055487. PubMed ID: 35110323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Pharmacist's Expanding Role in HIV Pre-Exposure Prophylaxis.
    Farmer EK; Koren DE; Cha A; Grossman K; Cates DW
    AIDS Patient Care STDS; 2019 May; 33(5):207-213. PubMed ID: 31067124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistence With Human Immunodeficiency Virus Pre-exposure Prophylaxis in the United States, 2012-2017.
    Huang YA; Tao G; Smith DK; Hoover KW
    Clin Infect Dis; 2021 Feb; 72(3):379-385. PubMed ID: 33527117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
    Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA;
    Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV pre-exposure prophylaxis provision by U.S. health centers in 2021.
    Chinbunchorn T; Mayer KH; Campbell J; King D; Krakower D; Marcus JL; Grasso C; Keuroghlian AS
    AIDS; 2024 Mar; 38(3):415-420. PubMed ID: 37905992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brief Report: Incidence of HIV in a Nationwide Cohort Receiving Pre-exposure Prophylaxis for HIV Prevention.
    Van Epps P; Wilson BM; Garner W; Beste LA; Maier MM; Ohl ME
    J Acquir Immune Defic Syndr; 2019 Dec; 82(5):427-430. PubMed ID: 31714421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Persons-United States, 2010-2014.
    Wu H; Mendoza MC; Huang YA; Hayes T; Smith DK; Hoover KW
    Clin Infect Dis; 2017 Jan; 64(2):144-149. PubMed ID: 27986691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
    Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
    Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Integrated Examination of County- and Individual-Level Factors in Relation to HIV Pre-exposure Prophylaxis Awareness, Willingness to Use, and Uptake Among Men Who Have Sex with Men in the US.
    Li J; Berg CJ; Kramer MR; Haardörfer R; Zlotorzynska M; Sanchez TH
    AIDS Behav; 2019 Jul; 23(7):1721-1736. PubMed ID: 30430340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. State health policies and interest in PrEP: evidence from Google Trends.
    Farkhad BF; Nazari M; Chan MS; Albarracín D
    AIDS Care; 2022 Mar; 34(3):331-339. PubMed ID: 34191662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-exposure and postexposure prophylaxis access in rural versus urban pharmacies in Georgia and Pennsylvania.
    Kislovskiy Y; Pino N; Crawford ND; Woitas T; Cason S; Konka A; Kimble T; Olson I; Villarreal D; Jarlenski M
    J Am Pharm Assoc (2003); 2024; 64(4):102084. PubMed ID: 38574992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individual and community-level benefits of PrEP in western Kenya and South Africa: Implications for population prioritization of PrEP provision.
    Mudimu E; Peebles K; Mukandavire Z; Nightingale E; Sharma M; Medley GF; Klein DJ; Kripke K; Bershteyn A
    PLoS One; 2020; 15(12):e0244761. PubMed ID: 33382803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increasing Access to Pre-Exposure Prophylaxis Among Transgender Women and Transfeminine Nonbinary Individuals.
    Klein A; Golub SA
    AIDS Patient Care STDS; 2019 Jun; 33(6):262-269. PubMed ID: 31166785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telehealth Models for PrEP Delivery: A Systematic Review of Acceptability, Implementation, and Impact on the PrEP Care Continuum in the United States.
    Bonett S; Li Q; Sweeney A; Gaither-Hardy D; Safa H
    AIDS Behav; 2024 Sep; 28(9):2875-2886. PubMed ID: 38856846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interest in HIV pre-exposure prophylaxis in men who have sex with men in West Africa (CohMSM ANRS 12324 - Expertise France).
    Coulaud PJ; Sagaon-Teyssier L; M'madi Mrenda B; Maradan G; Mora M; Bourrelly M; Dembélé Keita B; Keita AA; Anoma C; Babo Yoro SA; Dah TTE; Coulibaly C; Mensah E; Agbomadji S; Bernier A; Couderc C; Laurent C; Spire B;
    Trop Med Int Health; 2018 Oct; 23(10):1084-1091. PubMed ID: 30055043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Willingness to Take, Use of, and Indications for Pre-exposure Prophylaxis Among Men Who Have Sex With Men-20 US Cities, 2014.
    Hoots BE; Finlayson T; Nerlander L; Paz-Bailey G;
    Clin Infect Dis; 2016 Sep; 63(5):672-7. PubMed ID: 27282710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.